Matrix metalloproteinases (MMPs) have been traditionally implicated in cancer progression because of their ability to degrade the extracellular matrix. However, some members of the MMP family have recently been identified as proteases with antitumor properties. Thus, it has been described that collagenase-2 (MMP-8) has a protective role in tumor and metastasis progression, but the molecular mechanisms underlying these effects are unknown. We show herein that Mmp8 expression causes a decrease in miR-21 levels that in turn leads to a reduction in tumor growth and lung metastasis formation by MDA-MB-231 (4175) breast cancer cells. By using both in vitro and in vivo models, we demonstrate that the mechanism responsible for these MMP-8 beneficial effects involves cleavage of decorin by MMP-8 and a subsequent reduction of transforming growth factor b (TGF-b) signaling that controls miR-21 levels. In addition, miR-21 downregulation induced by MMP-8 increases the levels of tumor suppressors such as programmed cell death 4, which may also contribute to the decrease in tumor formation and metastasis of breast cancer cells overexpressing this metalloproteinase. These findings reveal a new signaling pathway for cancer regulation controlled by MMP-8, and contribute to clarify the molecular mechanisms by which tumor-defying proteases may exert their protective function in cancer and metastasis.
INTRODUCTION
Proteases constitute a heterogeneous group of enzymes that have the ability to hydrolyze peptide bonds. 1 Owing to the irreversible nature of the biochemical reaction catalyzed by these enzymes, protease signaling pathways are tightly regulated both at the transcriptional level and at different posttranscriptional steps, such as modulation of protease activation and expression of protease inhibitors. [2] [3] [4] Accordingly, changes in protease expression and activity can lead to many pathological conditions, including cancer. 5 Among the large and growing number of proteases associated with human malignancies, matrix metalloproteinases (MMPs) have attracted considerable interest because of their extraordinary ability to degrade most components of the extracellular matrix, facilitating the breakdown of tissue barriers by tumor cells. However, and somewhat unexpectedly, further studies have demonstrated that some members of the MMP family, such as MMP-8, may have protective roles during tumor progression. 5, 6 MMP-8 or collagenase-2 is a metalloproteinase mainly produced by neutrophils where it is stored in intracellular granules and activated under inflammatory conditions. This protease efficiently degrades fibrillar collagens, 7 but also targets other extracellular matrix proteins, chemokines, growth factors, cell adhesion proteins, protease inhibitors as well as other proteases. 8, 9 Interestingly, several studies with mouse models and cancer patients have demonstrated that MMP-8 may favor the host instead of the tumor. In fact, Mmp8-deficient mice are more susceptible to develop skin tumors than control mice. 6 Moreover, MMP-8 expression is associated with increased survival rate of patients with tongue cancer, 10 as well as with a lower incidence of lymph node infiltration in breast cancer patients. 11 Nevertheless, despite this evidence indicating a protective effect of MMP-8 during tumor progression, the molecular mechanisms underlying these protective roles remain unknown.
Tumor invasion and metastasis are complex processes that arise when cancer cells acquire the ability to degrade the extracellular matrix, thus escaping from the primary tumor and penetrating into the blood circulation. Over the last years, numerous studies have identified a series of genes associated with metastasis formation. 12, 13 However, how these genes are functionally connected to generate metastatic tumors and how tissue specificity of metastasis is determined are still important questions that need to be clarified. 14 Since the discovery of microRNAs (miRNAs) as small non-coding RNAs that provide a new regulatory mechanism for biological processes, there has been a great effort to define their roles in cancer and metastasis. 15 miRNAs modulate molecular pathways involved in cancer by targeting different tumor suppressors and oncogenes. 16 Moreover, they have a relevant function in controlling angiogenesis, epithelial-mesenchymal transition, biology of cancer stem cells, metastasis and drug resistance. 17 A remarkable onco-miRNA is miR-21, that is highly expressed in several types of cancer, 18 and controls different genes implicated in cancer progression, such as maspin, tropomyosin 1, phosphatase and tensin homolog (PTEN), and programmed cell death 4 (PDCD4). [19] [20] [21] Recently, it has been described that miR-21 and PDCD4 are implicated in the control of inflammation and tumor progression through a pathway, which involves sequestration of transforming growth factor b1 (TGF-b1) by decorin. 22 As some members of the MMP family are capable to cleave several components of the extracellular matrix including decorin, 23 we hypothesized that MMP-8 could activate decorin, leading to a downregulation of active TGF-b1 and miR-21 levels, which could in turn result in a reduction of metastasis formation.
In this work, we have explored the anti-metastatic function of MMP-8 by using a previously established model of MDA-MB-231 human breast cancer cells, which are highly metastatic to lung. 24 We demonstrate that expression of Mmp8 is sufficient to reduce the metastatic activity of these cells, in a process that requires downregulation of active TGF-b1 and miR-21, and is mediated by MMP-8 activation of decorin. These results have also been extended to SK-BR-3 breast cancer cells and suggest that regulation of miR-21 levels by MMP-8 is critical for this metalloproteinase to exert its antimetastatic role. Collectively, these findings provide new insights into the mechanisms by which tumor-suppressive proteases develop protective functions in cancer.
RESULTS
MMP-8 delays tumor growth and reduces lung metastasis formation in breast cancer cells Previous studies have described MMP-8 as a metalloproteinase with antitumor and anti-metastatic properties. 6, 11 To explore the molecular mechanisms responsible for this protective role of MMP-8 in cancer, we used human MDA-MB-231 cells, and more specifically the line 4175 (LM2), which is highly metastatic to lung. 24 To evaluate the antitumor and anti-metastatic capacities of MMP-8 in this cell line, we transfected 4175 (LM2) cells with the murine Mmp8 complementary DNA (cDNA) and isolated several stable transfectant clones that expressed the gene. We decided to use two of these clones (clones 3 and 8) for further studies, as they had a high Mmp8 expression as well as high firefly luciferase activity to monitor metastasis formation in vivo. Quantitative reverse transcriptase (qRT-PCR) and western blot analysis confirmed the expression of MMP-8 in both clones, but not in cells transfected with an empty vector (control cells; Figure 1a ). In addition, by using a dual-luciferase reporter assay, we demonstrated a similar expression of the luciferase enzyme in clones and control (Figure 1b) .
Mmp8 stable-transfected cells and control cells were injected in the mammary fat pad of nude mice and their tumorigenic capacity was analyzed as previously described. 24 As shown in Figure 1c , mice injected with cells expressing Mmp8 showed a significantly reduction in tumor growth when compared with control cells, reinforcing the idea that the metalloproteinase has a protective function against tumor development (Supplementary Figure 1a) . To study the effect of MMP-8 on metastasis formation, we injected either control cells or cells overexpressing Mmp8 in the tail vein of nude mice to evaluate the cells capacity to colonize the lungs. The metastatic lung colonization activity was assayed by bioluminescence imaging of luciferase-transduced cells as well as by ex vivo examination of the lungs at necropsy followed by Anti-metastatic activity of MMP-8 mediated by decorin and miR-21 C Soria-Valles et al histological analysis. The intensity of the bioluminescence signal at day 41 was 6 times lower in mice injected with clone 3 and 14 times lower in those injected with clone 8, when compared with the respective controls (Figure 1d ). In addition, histological analysis revealed that mice injected with clones 3 and 8 had a lower number of metastatic foci and with a smaller size when compared with mice injected with control cells (Figure 1d ). This difference was more remarkable in those mice injected with clone 8, which had a higher expression of Mmp8 (Figures 1a and d;  Supplementary Figure 1b) analyzed whether the migration properties of these tumor cells were altered. For this aim, we performed wound-healing assays in vitro, showing that 10 h after wounding, control cells had migrated 14% more than clone 3 and 26% more than clone 8 (Figure 2a ), suggesting that MMP-8 modifies the migration properties of tumor cells. Furthermore, proliferation assays revealed that cell proliferation was higher in control cells than in clones overexpressing Mmp8 (Figure 2b ), which might explain the delay in the in vivo growth of tumors generated by these transfected cells. In agreement with the above results, proliferation differences were more significant in clone 8, which had the highest expression levels of Mmp8, suggesting a direct relation between levels of this metalloproteinase and reduction in cell proliferation. The expression of Mmp8 also resulted in changes in the invasive properties of MDA-MB-231 breast cancer cells. Thus, by using Matrigel-coated transwell invasion assays, we observed that overexpression of Mmp8 led to a reduction in the invasive ability of these cells through Matrigel when compared with control cells (Figure 2c ).
MMP-8-suppressive effect on cell migration, proliferation and invasion relies on its metalloproteinase activity as demonstrated (10 4 ) were seeded on Matrigel-coated transwells and incubated for 18 h using 5% fetal bovine serum as chemoattractant. Cells were fixed with methanol and stained using crystal violet, counted and photographed in nine random fields under a bright field microscope. Plot data are relative mean values expressed as a percentage ± s.e.m. (n ¼ 3, **Po0.01, two-tailed Student's t-test).
by the fact that MDA-MB-231 cells expressing a mutant Mmp8 (E218Q) 11 that completely abolishes MMP activity showed similar properties to the control MDA-MB-231 cells ( Supplementary  Figures 2a-c ).
MMP-8 decreases miR-21 expression in MDA-MB-231 cells
To further investigate the molecular mechanisms implicated in the anti-metastatic activity of MMP-8, and because of the emerging role of miRNAs in cancer development and progression, 15 we performed a miRNA expression analysis of breast cancer cells in the presence or absence of MMP-8. We found that Mmp8-expressing cells induced the expression of some miRNAs including miR-149-3p, miR-1228-5p, miR-885-3p and miR638, and downregulated the expression of miR-433, miR-570, miR-30a-5p, miR-22, miR-923 and miR-21 ( Figure 3a ; Supplementary Table 1) . Among all these miRNAs whose expression levels were altered as a consequence of Mmp8 overexpression, we focused on miR-21 because of its remarkable role as an oncomir. 19 First, we confirmed by qRT-PCR that the expression of miR-21 was diminished in cells overexpressing Mmp8 (clones 3 and 8) when compared with control cells (Figure 3b ). Furthermore, similar results were obtained when these cells were injected in nude mice to induce experimental lung metastasis, where a reduction of miR-21 levels in those mice injected with Mmp8-overexpressing cells was confirmed ( Figure 3c ). Mmp8-specific knockdown in MDA-MB-231 clones 3 and 8 by using small interfering RNAs (siRNAs; Supplementary Figure 3a) significantly increased miR-21 levels, demonstrating the causal role of this protease in the regulation of the oncomir levels ( Figure 3d) . A similar effect was seen when batismastat, a specific inhibitor of MMPs was used (Supplementary Figure 3b) .
Suppression of miR-21 expression in MDA-MB-231 breast cancer cells has been reported to reduce invasion and lung metastasis, increasing the expression of different tumor suppressors in human breast carcinomas. 19 To investigate the biological role of this miRNA in the experimental system used, we overexpressed miR-21 Figure 4a) , and the tumorigenic capacity was analyzed by injecting these cells into the mammary fat pad of nude mice. As shown in Figure 3f , no significant differences in tumor growth were observed between control cells and Mmp8-expressing cells (clones 3 and 8) as a consequence of miR-21 overexpression. We next assayed in vivo the ability of these cells to colonize the lungs by injecting them in the lateral tail vein of nude mice (Figure 3g) . Interestingly, the incidence of experimental lung metastasis, analyzed by bioluminescence image and histological analysis, was similar in both control cells and cells overexpressing Mmp8 (Figure 3g ), without changes in Mmp8 levels (Supplementary Figure 4b) , indicating that miR-21 expression reverts the anti-metastatic activity of this protease, and suggesting that this miRNA could be the main downstream effector of MMP-8. miR-21 expression revert the effect of MMP-8 on cellular processes associated with tumor progression To further investigate whether miR-21 could modify any of the cellular processes affected by the activity of MMP-8, we conducted a series of in vitro experiments using the above modified breast cancer cells. We observed that miR-21 was able to change the migration, invasion and proliferation rates of cells expressing Mmp8. In fact, miR-21 overexpression abrogated the inhibitory effects of MMP-8, increasing the ability of clones 3 and 8 to migrate and reaching similar levels to control cells (Figure 4a ). Similar effects were observed when cell proliferation was analyzed. Thus, cells expressing Mmp8 increased their proliferation rate in culture to the same level as control cells (Figure 4b ). The invasive capacity of Mmp8-expressing cells was also increased by miR-21 overexpression, reaching similar levels to control cells (Figure 4c ). These results suggest that miR-21 levels modify the functional effects of the metalloproteinase MMP-8 on cellular processes associated with tumor progression.
MMP-8 reduces miR-21 expression through decorin cleavage
Recently, a molecular link between proteoglycans of the extracellular matrix and miRNAs has been established, after the finding that decorin controls inflammation and tumor growth through a process involving miR-21 and PDCD4. 22 As some members of the Anti 23 we analyzed whether this proteoglycan is expressed in our model cell line MDA-MB-231 (4175). Thus, decorin expression was detected at both RNA and protein levels, as assessed by qRT-PCR and western blot analysis, respectively (Figure 5a ). Furthermore, we observed an accumulation of the core protein (40 kDa) associated with Mmp8 expression when compared with control cells (Figure 5a ). These results seemed to indicate that MMP-8 was able to process decorin, supporting previous studies showing some proteolytic activity of MMP-8 on this protein. 23 Therefore, we decided to analyze whether MMP-8 can process decorin in vitro. To this purpose, we incubated both human recombinant proteins, observing a specific cleavage of decorin by MMP-8, yielding a 40 kDa band, which corresponds to the core protein (Figure 5b) . Figures 5a-c) .
Decorin is a matrix protein known to sequester growth factors, such as TGF-b1, blocking the interaction with its membrane receptors and interfering with the expression of miR-21. 22 Accordingly, we observed a decrease in TGF-b1 active levels in clones 3 and 8 as compared with the control MDA-MB-231 (Figure 5c ). These results suggest that decorin is activated by MMP-8; processed decorin binds TGF-b1 and prevents its activation. To test whether the effect of MMP-8 on miR-21 expression could be mediated by TGF-b1, we incubated control cells and Mmp8-expressing clones with this recombinant protein, and the expression of miR-21 was evaluated by qRT-PCR after 48 h in culture. As shown in Figure 5d , addition of recombinant TGF-b1 increased miR-21 expression in both control cells and Mmp8-expressing clones when compared with untreated cells. 
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Consequently, cells expressing mutant MMP-8 showed similar TGF-b1 active levels to the control cells and its miR-21 expression levels respond in the same way to TGF-b1 stimulation ( Supplementary Figures 5d and e) . Moreover, TGF-b signaling inhibition with SB-431542 was able to reduce miR-21 levels in these cells (Figure 5e ).
Further validation of decorin involvement was obtained through siRNA transfection (Supplementary Figure 5f) . Thus, decorin knockdown increased the levels of active TGF-b1 in both control and Mmp8 MDA-MB-231-expressing cells (Figure 5f ), modulating miR-21 levels (Figure 5g ).
To identify putative factors that could be mediating the reduction in tumor formation and metastasis exerted by MMP-8, we also performed proteomic approaches through two-dimensional difference gel electrophoresis (2D-DIGE) and matrix-assisted laser desorption/ionization-time of flight analysis. We found that MMP-8 modifies the expression of several proteins, such as macrophage-capping protein, 60S acidic ribosomal protein P0, protein Z-dependent protease inhibitor, poly (rC)-binding protein 1 and 26S protease regulatory subunit S10B (Supplementary Figure 6a) . One of these modified proteins was PDCD4, a proinflammatory cytokine that acts as a tumor suppressor by inhibiting neoplastic transformation and tumor progression, and that has been reported as a bona fide target of miR-21. 25 Western blot analysis in control and Mmp8 MDA-MB-231 showed that PDCD4 expression is increased in Mmp8-expressing cells as compared with controls ( Figure 5h ) but no changes were detected between control cells and cells expressing E218Q-Mmp8 (Supplementary Figure 6b) . According to the mechanism described, miR-21 overexpression decreased PDCD4 levels, reverting the MMP-8 effect (Figure 5i) ; on the other hand, TGF-b signaling inhibition increased PDCD4 levels (Supplementary Figure 6c) .
MMP-8 regulates miR-21 levels through a conserved mechanism
In order to extend the results obtained in MDA-MB-231 cells, we generated an Mmp8 stable expressing SK-BR-3 cell line, another estrogen receptor-negative breast cancer cell line. MMP-8 expression was confirmed by qRT-PCR and western blot analysis (Supplementary Figure 7a) . Mmp8-expressing SK-BR-3 cells showed downregulation of miR-21, higher levels of processed decorin, decreased availability of active TGF-b1 and increased PDCD4 expression as compared with control SK-BR-3 cells (Supplementary Figures 7b-e) . In addition, incubation of SK-BR-3 cells with recombinant TGF-b1 increased miR-21 levels (Supplementary Figure 7f) . These results show that miR-21 is the main effector of MMP-8 activity in this cell line.
DISCUSSION
For several decades, proteases have been implicated in tumor growth and metastasis. However, our view of the functional relevance of proteolytic systems in these processes has substantially evolved after the finding that some members of different protease families can have protecting functions in cancer. Collagenase-2 (MMP-8) was the first MMP described to have antitumor and anti-metastatic capacities during cancer progression, 6, 11, 26 but the molecular mechanisms underlying these positive effects mediated by MMP-8 remain largely unclear. In this work, we have shown that this extracellular protease reduces tumor growth and metastasis because of its ability to regulate miR-21 levels by processing decorin, a proteoglycan of the extracellular matrix that blocks TGF-b signaling. miR-21 downregulation causes an increase in the levels of the tumorsuppressor PDCD4 and contributes to the tumor-defying properties of MMP-8 metalloproteinase (Figure 6 ).
The elucidation of this novel signaling pathway in cancer was first based on the generation of Mmp8 stable transfectants in highly metastatic MDA-MB-231 (4175) breast cancer cells. 24 In vivo experiments showed that Mmp8 overexpression significantly delayed the growth of mammary tumors generated by these cells. Moreover, the number of experimental lung metastases was also diminished in mice injected with different clones of Mmp8-overexpressing breast cancer cells. To address the Figure 6 . A model depicting MMP-8-decorin-miR-21 signaling pathway in breast cancer. MMP-8 and decorin are secreted to the extracellular matrix. In this context, MMP-8 cleaves decorin, releasing the core protein, which is able to sequester TGF-b1. Decreased availability of TGF-b1 in the extracellular media results in a reduction in miR-21 levels. As a consequence of the reduction in miR-21 levels, several tumor-suppressor genes are derepressed including PDCD4, which may contribute to the reduction in tumor growth and metastasis.
Anti-metastatic activity of MMP-8 mediated by decorin and miR-21 C Soria-Valles et al molecular mechanisms implicated in these protective roles mediated by MMP-8, we first performed in vitro proliferation, migration and invasion assays with the finding that the overexpression of this metalloproteinase in breast cancer cells significantly altered all these properties, pointing to the occurrence of a broad effect of MMP-8 overexpression in the behavior of these cells. Then, and because the growing relevance of miRNAs in all stages of cancer, 15 we performed an expression analysis of miRNAs, looking for putative components of this complex regulatory system, which could be affected by the overexpression of Mmp8. This microarray-based analysis revealed that the overexpression of this metalloproteinase causes a marked downregulation of miR-21 levels in MDA-MB-231 (4175) breast cancer cells. Interestingly, previous works had shown that miR-21 knockdown inhibits proliferation and migration of MCF7 and MDA-MB-231 cells in vitro, and tumor growth and lung metastasis in vivo.
19,27 Accordingly, we observed that overexpression of miR-21 in breast cancer cells was sufficient to counteract the in vitro effect of MMP-8 on migration, proliferation and invasion of these cells. Furthermore, in vivo experiments extended these observations and demonstrated that miR-21 overexpression abolished the antitumor and anti-metastatic effect of MMP-8. Collectively, these results strongly suggested that miR-21 was a bona fide downstream effector of MMP-8.
In this regard, previous studies have shown that miR-21 expression is activated in several human malignancies including breast carcinomas, and regulates molecular pathways implicated in cell survival, apoptosis and invasiveness. 18, 28, 29 Although TGF-b exhibits an anti-proliferative role in early steps of oncogenesis, it has been well documented to display pro-metastastic activity by promoting epithelial-mesenchymal transition and metastatic behavior of cancer cells through a mechanism involving miR-21 induction. 30 Consistently, high levels of miR-21 in breast cancer patients are associated with high levels of TGF-b and reduced disease-free survival of these patients. 31 Furthermore, decorin controls inflammation and tumor progression through PDCD4 and miR-21. 22 On this basis, together with the fact that decorin can be proteolytically processed by several MMPs, we speculated that this proteoglycan could be an in vivo substrate of MMP-8, which after cleavage and activation, could block this TGFb-mediated signaling pathway and cause the observed miR-21 downregulation in metastatic breast cancer cells. In fact, after checking that MDA-MB-231 (4175) cells expressed significant amounts of decorin, we could confirm that recombinant MMP-8 cleaves this proteoglycan generating a fragment corresponding to the 40 kDa core protein.
We could also corroborate that MMP-8 has a direct impact on TGFb signaling in these metastatic cells by observing that Mmp8-overexpressing cells showed reduced levels of active TGF-b1. Moreover, we observed that incubation of control cells and clones with recombinant TGF-b1 increased miR-21 levels. Taken together, these results are consistent with our proposal that decorin activation by MMP-8 alters TGF-b signaling and blocks the expression of the downstream effector miR-21. By using a proteomic approach, we found that downregulation of miR-21 altered the expression of PDCD4 in Mmp8-overexpressing cells, providing further evidence that the anti-metastatic effect of this metalloproteinase could be mediated, at least in part, by PDCD4 tumor suppressor. The described mechanism was also validated in SK-BR-3 breast cancer cells, thus ruling out the possibility that it was specifically operating in MDA-MB-231 cells.
Over the past years, the link between cancer progression and metalloproteinases was strongly sustained on the collagenolytic ability of some of these enzymes, which contributes to degrade the basement membrane, thereby facilitating tumor growth and invasion. 32, 33 Our current understanding of MMPs shows that substrate specificity of these enzymes is not only limited to components of the extracellular matrix but also to a wide range of substrates leading either to their proteolytic inactivation or to an increase of their biological activities. 3 In this work, we have shown that MMP-8 is able to modify the metastatic potential of breast cancer cells because of its ability to proteolytically cleave decorin and regulate miR-21 levels. These results provide new insights on the mechanisms by which MMP-8 exerts its protective function against in progression and may open future possibilities to increase the expression and activity of this metalloproteinase as part of combined strategies to treat metastatic tumors.
MATERIALS AND METHODS

Animal studies
All the animal work was done in accordance with the guidelines of the Committee for Animal Experimentation of the Universidad de Oviedo. Balb/c nude mice (Charles River Laboratories International, Inc., Wilmington, MA, USA) 4-6 weeks old were used for all xenograft studies. For mammary fat pad tumor assays, cells were harvested by trypsinization, washed twice in phosphate-buffered saline (PBS) and counted. Cells were then resuspended (10 7 cells/ml) in a 50:50 solution of PBS and Matrigel (BD Biosciences San Jose, CA, USA). Mice were anesthetized and a small incision was made to reveal the mammary gland, injecting 10 6 cells directly into the mammary fat pad. The incision was closed sewing the wound with surgical thread and primary tumor outgrowth was monitored weekly by measuring tumor length (L) and width (W). Tumor volume was calculated as pLW 2 /6. We considered the endpoint of the experiment when the tumors reached a volume 4300 mm 3 . For lung metastasis formation, 2 Â 10 5 viable cells were washed and harvested in PBS, and subsequently injected into the lateral tail vein in a volume of 0.1 ml. Mice were imaged for luciferase activity immediately after injection to exclude any animal that was not successfully xenografted. Endpoint assays were conducted around 6-9 weeks after injection. Cell culture and siRNA delivery For transfection of small interference RNAs, we followed manufacturer's instructions (Stealth siRNAs, Life Technologies). Briefly, cells were plated at low density (30-50%) and up to 150 pg of siRNA were added with 7.5 ml of lipofectamine RNAiMAX (Life Technologies). The analyses were performed 48 h after the first transfection. Cells were incubated either with TGF-b inhibitor SB-431542 (Sigma, Lyon, France; 10 mM) during 48 h or batismatat (BB-94; 5 mM) during 24 h before the analysis. Cells from control and Mmp8-overexpressing cells were incubated with 5 ng/ml of human recombinant TGF-b1 (10811016, Life Technologies) during 48 h. All the incubations were done in serum-free Dulbecco's modified Eagle's medium culture media.
Generation of stable transfectant cells
Bioluminescence analysis
Mice were anesthetized and injected intraperitoneally with 200 ml of D-luciferin solution (15 g/l in PBS, Melford Laboratories Ltd, Suffolk, UK). Imaging was completed between 2 and 5 min after injection, using a Xenogen IVIS system and the Living Image acquisition and analysis Anti-metastatic activity of MMP-8 mediated by decorin and miR-21 C Soria-Valles et al software (Xenogen, PerkinElmer, Waltham, MA, USA). Photon flux was calculated for each mouse using a rectangular region of interest. This value was scaled for each mouse to a comparable background value (from a luciferin-injected mouse with no tumor cells), and then normalized to the value obtained immediately after xenografting (day 0), so that all mice had an arbitrary starting bioluminescence imaging signal of 1000.
RNA preparation and qRT-PCR
Total RNA from cells and tissue samples was extracted using TRIzol reagent (Life Technologies), and processed through alcohol precipitation. RNA pellets were then washed in cold 75% ethanol, and resuspended in nuclease-free water (Life Technologies). The samples were quantified and evaluated for purity (260/280 nm ratio) with a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA). miR-21 detection was performed by triplicate using Taqman miRNA expression assays (Life Technologies). Briefly, 10 ng of total RNA was reverse transcribed using Taqman miRNA reverse transcription kit (Life Technologies) and PCR amplified using an Applied Biosystems 7300 Real-Time PCR system (Life Technologies). As an internal control, miRNA expression was normalized to RNU6B for human samples using Taqman Gene Expression Assays (Mm00439509_m1, Life Technologies). All protocols were carried out according to the manufacturer's instructions. Mmp8 mRNA levels were measured by qRT-PCR using a specific Taqman probe. cDNA was synthesized with 1 mg of total RNA with the ThermoScript RT-PCR System (Life Technologies). As an internal control for the amount of template cDNA used, gene expression was normalized to amounts obtained for the human b-actin endogenous control. Decorin expression was analyzed using 2 mg of total RNA for cDNA synthesis with the ThermoScript RT-PCR (Life Technologies). qRT-PCR was carried out in triplicate for each sample with 30 ng of cDNA, Power SYBR green PCR Master Mix and 0.5 ml of the specific oligonucleotides for each gene of interest. Gene expression was normalized with human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as endogenous control. The following oligonucleotides (Sigma) were used for human decorin and GAPDH amplification:
Luciferase assays Determination of luciferase activity was performed using Dual-luciferase Reporter Assay System (Promega, Madison, WI, USA) following the kit instructions. Firefly luciferase activity of each sample was measured in a TD-20/20 luminometer (Turner Biosystems, Promega).
Wound-healing assays
Cells were seeded over the wells of a six-well plate and they were allowed to reach confluence before dragging a 10 ml sterile pipette tip through the monolayer. Cells were washed to remove cellular debris and allowed to migrate for 24 h. Images were taken at time 0, 5, 19 and 24 h postwounding using a digital camera system (Leica EC3; Leica Microsystems, Bannockburn, IL, USA). The motility of the cells was determined as repaired area percentage using ImageJ software to calculate the area and considering time 0 as a blank. Data are the mean of three different areas measured in the same well and three replicates of each cell group.
Cell proliferation assays
To quantify cell proliferation, a CellTiter96AQ nonradioactive cell proliferation kit was used (Promega). Three replicates of 2000 cells were seeded in 96-well plates for each one of the cell groups and incubated at 37 1C, 5% CO 2 for 4 days. Cell proliferation was quantified by measuring the conversion of 3-(4,5-dimethyl thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) into a water-soluble formazan by dehydrogenase enzyme in living cells, and the absorbance was measured at 490 nm using a microplate reader.
Cell invasion assays
The in vitro invasion potential was evaluated using Matrigel-coated invasion chambers with an 8-mm pore size (BD Biosciences). Then, 10 4 cells were allowed to migrate for 18 h through each Matrigel-coated membrane using 5% fetal bovine serum as chemoattractant. Cells that reached the lower surface of the membrane were stained and counted in nine random fields per insert (magnification, Â 4) to determine the total number of cells in the lower chamber. Data are the mean of three replicates for each cell group.
Microarray analysis
The oligonucleotide sequences corresponding to 2054 mature miRNAs (including 409 Homo sapiens miRNAs) found in the miRNA registry (release 8.2) are available on http://www.microarray.fr:8080/merge/index (follow the link to 'microRNA': platform referenced in GEO accession numbers GPL4718). The experimental design used a dye-swap approach, so that each human probe, printed 8 times on the microarray was measured independently 16 times for each sample. Target preparation and array hybridization were performed as previously described. 34 Normalization was performed using the Limma package available from Bioconductor (http://www.bioconductor.org). Intra-and inter-slide normalization was performed using the Print Tip Loess and the quantile methods, respectively. Means of ratios from all comparisons were calculated and B test analysis was performed. Differentially expressed genes were selected using Benjamini-Hochberg correction of the P-value for multiple tests, based on a Po0.01. Heat maps were created using TreeView 1.1.5 software (http://rana.lbl.gov/EisenSoftware.htm).
Western blot analysis
In all, 1 Â 10 6 cells were seeded in six-well plates and supernatants were collected after 48 h. Then, cells were precipitated with acetone overnight at -20 1C. The following day, samples were pelleted by centrifugation and resuspended in loading buffer. Cultured cells were washed twice with PBS and resuspended in 100 mM Tris-HCl (pH 7.4), 2% sodium dodecyl sulfate, 50 mM EDTA, 1 mM Na 2 VO 4 , 1mM NaF and 1 mM b-glycerolphosphate. Protein concentration was evaluated with the bicinchoninic acid technique (Pierce BCA Protein Assay Kit; Thermo Scientific). Equal amounts of proteins were loaded onto sodium dodecyl sulfate-polyacrylamide gels. After electrophoresis, gels were electrotransferred onto nitrocellulose membranes (Millipore, Billarica, MA, USA) blocked with 5% nonfat dry milk in Tris-Buffered Saline and Tween 20 (TBS-T) buffer (20 mM Tris (pH 7.4), 150 mM NaCl and 0.05% Tween 20), and incubated overnight at 4 1C with the different primary antibodies (PDCD4, 9535S from Cell Signaling (Danvers, MA, USA); decorin, ab54728 from Abcam (Cambridge, MA, USA); b-actin clone AC-40, A3853 from Sigma; and MMP-8 (provided by G Murphy, UEA-UK)). Then, membranes were incubated with 1:10 000 secondary antibody conjugated with horseradish peroxidase (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) in 1.5% nonfat milk in Tris-Buffered Saline and Tween 20. Finally, the blots were washed and developed the immunoreactive bands with immobilon western chemiluminescent horseradish peroxidase substrate (Millipore).To confirm that the MMP-8 proenzyme, but not the MMP-8 E218Q mutant was autoprocessed to its active form, the conditioned medium was incubated with 4-aminophenylmercuric acetate at 37 1C for 1 h and subsequently analyzed by western blot.
Proteolytic activity assays
For experiments involving the use of recombinant MMP-8, the protein was produced and purified as previously described. 35 MMP-8 proenzyme was converted into the active form after activation with 4-aminophenylmercuric acetate. For decorin cleavage experiments, 1 mg of active MMP-8 was incubated with 400 ng of recombinant human decorin (H00001634-P01, Abnova, Taipei, Taiwan) overnight at 37 1C. Finally, samples were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
ELISA
One million cells from each line were plated over 6 cm dishes and incubated with serum-free Dulbecco's modified Eagle's medium culture media for 48 h. After this time, supernatants were collected and used for measuring TGF-b1 concentrations through an ELISA assay (DB100B, R&D Systems, Minneapolis, MN, USA) following the manufacturer's instructions. 
